PNC Financial Services Group Inc. Acquires 726 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

PNC Financial Services Group Inc. raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,097 shares of the specialty pharmaceutical company’s stock after buying an additional 726 shares during the period. PNC Financial Services Group Inc.’s holdings in Supernus Pharmaceuticals were worth $527,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. GW&K Investment Management LLC boosted its holdings in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company’s stock worth $45,275,000 after buying an additional 176,091 shares during the period. Northern Trust Corp lifted its position in Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company’s stock worth $25,933,000 after buying an additional 110,867 shares during the last quarter. Ashford Capital Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 0.3% during the 4th quarter. Ashford Capital Management Inc. now owns 545,775 shares of the specialty pharmaceutical company’s stock worth $19,735,000 after purchasing an additional 1,740 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of Supernus Pharmaceuticals by 33.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company’s stock worth $19,731,000 after buying an additional 136,870 shares during the period. Finally, Invesco Ltd. increased its stake in Supernus Pharmaceuticals by 4.5% in the fourth quarter. Invesco Ltd. now owns 508,069 shares of the specialty pharmaceutical company’s stock worth $18,372,000 after purchasing an additional 22,027 shares during the period.

Supernus Pharmaceuticals Trading Up 3.4%

SUPN opened at $42.64 on Thursday. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of 37.08 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $43.62. The business’s fifty day simple moving average is $33.99 and its 200-day simple moving average is $33.53.

Analyst Ratings Changes

Several research analysts recently commented on SUPN shares. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 140,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares of the company’s stock, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.